Jun 07, 2023 / 01:00PM GMT
Kelly Shi - Jefferies - Analyst
Okay. We're going to start. Good morning, everyone, and my name is Kelly Shi, one of the biotech analysts at Jefferies. And thanks, everyone, for attending Jefferies New York Healthcare Conference, and please join me and welcome Mr. Mark Enyedy, President and CEO, and Dr. Anna Berkenblit, CMO, of ImmunoGen.
Mark Enyedy - ImmunoGen, Inc. - President & CEO
Thank you.
Kelly Shi - Jefferies - Analyst
And long time, no see.
Mark Enyedy - ImmunoGen, Inc. - President & CEO
We were all together in Chicago.
Questions and Answers:
Kelly Shi - Jefferies - AnalystELAHERE is one of the most exciting stories in oncology space and congrats on the tremendous success you have achieved over last several years. And maybe we can start with a review of your ASCO presentation. What additional data from MIRASOL trial was presented there? And what has been the feedback from the physician community on the